Devises / ACAD
ACAD: ACADIA Pharmaceuticals Inc
25.99
USD
0.24
(0.91%)
Le taux de change de ACAD a changé de -0.91% aujourd'hui. Au cours de la journée, l'instrument a été échangé à un minimum de 25.82 et à un maximum de 26.30.
Suivez la dynamique ACADIA Pharmaceuticals Inc. Les cotations en temps réel vous aideront à réagir rapidement aux changements du marché. En basculant entre différentes périodes, vous pouvez surveiller les tendances et la dynamique des taux de change par minutes, heures, jours, semaines et mois. Utilisez ces informations pour prévoir les changements du marché et prendre des décisions de trading éclairées.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
ACAD Nouvelles
- Axsome Shares Up 20% in a Month: How Should You Play the Stock?
- Acadia Pharmaceuticals appoints Katcheves as chief business officer
- Acadia Pharmaceuticals stock hits 52-week high at $25.90
- JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
- Mizuho lowers Acadia Pharmaceuticals stock price target to $22 from $32
- Acadia Pharmaceuticals stock hits 52-week high at 25.24 USD
- Acadia Pharmaceuticals stock price target raised to $24 from $18 at Stifel
- Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
- Mizuho raises Acadia Pharmaceuticals stock price target on solid earnings
- Acadia Pharmaceuticals stock price target raised to $38 from $37 at Citizens JMP
- Acadia Pharmaceuticals Q2 2025 slides: revenue up 9%, raises full-year guidance
- Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates
- Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates
- Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
- Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
- Sarepta to Report Q2 Earnings: What's in Store for the Stock?
- GMAB vs. ACAD: Which Stock Is the Better Value Option?
- Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
- ACADIA Pharmaceutical: ACP-101 Read-Out Is Not Fully Priced In (NASDAQ:ACAD)
- Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
- Acadia stock price target raised to $32 from $22 at UBS on growth outlook
- Acadia Pharmaceuticals stock rating reiterated by H.C. Wainwright
- Acadia stock maintains outperform rating at RBC on pipeline potential
- Acadia Pharmaceuticals stock maintains outperform rating at BMO Capital
Range quotidien
25.82
26.30
Range Annuel
13.40
26.64
- Clôture Précédente
- 26.23
- Ouverture
- 26.19
- Bid
- 25.99
- Ask
- 26.29
- Plus Bas
- 25.82
- Plus Haut
- 26.30
- Volume
- 2.026 K
- Changement quotidien
- -0.91%
- Changement Mensuel
- 9.66%
- Changement à 6 Mois
- 32.00%
- Changement Annuel
- 57.04%
30 août, samedi